Effect of low-dose aspirin during pregnancy on fibrinolytic variables before and after parturition by Bremer, H.A. (Henk) et al.
Effect of low-dose aspirin during pregnancy on fibrinolytic 
variables before and after parturition 
Henk A. Bremer, MD,” Nel Rotmans, BSc,“t Emile J.P. Brommer, MD, PhD,b and 
Henk C.S. Wallenburg, MD, PhD 
Rotterdam and Leiden, The Netherlands 
OBJECTIVE: We assessed the effects of a daily oral dose of 60 to 80 mg of aspirin from 12 weeks’ 
gestation until delivery on fibrinolytic variables before and after parturition. 
STUDY DESIGN: In a prospective controlled study labor was electively induced in 24 patients, eight 
receiving low-dose aspirin and 16 controls. Levels were determined in maternal and cord plasma of 
tissue-type plasminogen activator antigen and activity, plasminogen activator inhibitor-l antigen, 
plasminogen activator inhibitor activity, and plasminogen activator inhibitor-2 antigen. We also determined 
metabolites of vascular prostacyclin and platelet thromboxane A,. 
RESULTS: The only maternal fibrinolytic variable affected by low-dose aspirin was plasminogen activator 
inhibitor activity, which showed a significant reduction before and after parturition of 40% and 70%, 
respectively, in low-dose aspirin users compared with controls. Concentrations of thromboxane B, in 
women using low-dose aspirin were 7% (maternal serum) and 17% (cord serum) of values in controls, but 
concentrations of 6-keto-prostaglandin F,, were not affected. 
CONCLUSIONS: Low-dose aspirin reduces plasminogen activator inhibitor activity and platelet reactivity, 
but not prostacyclin synthesis, before and after parturition. The reduction in plasminogen activator 
inhibitor activity may be caused by inhibition of platelet reactivity. (AM J OBSTET GYNECOL 1995;172:986-91.) 
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In recent years an increasing number of pregnant 
women at risk of pregnancy-induced hypertensive dis- 
orders and fetal growth retardation are being pre- 
scribed low-dose aspirin,’ although its prophylactic ef- 
fect remains disputed.‘-” Aspirin in analgesic doses may 
have an antifibrinolytic effect, because it inhibits the 
endothelial release of tissue-type plasminogen activator 
(tPA) after venous occlusion.‘~ ’ This effect could be 
mediated by inhibition of prostacyclin (PGI,) synthesis 
because it is reversed by a synthetic PGI, ana1og.7 
Low-dose aspirin, 20 mg for 7 days, did not afect 
fibrinolytic activity after venous occlusion in healthy 
males.8 Although low-dose aspirin primarily inhibits 
platelet thromboxane synthesis, it may also cause a 
small reduction in PGI, synthesis in nonpregnant indi- 
vidual? and in pregnant women.” For that reason an 
effect of long-term low-dose aspirin on the fibrinolytic 
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system of the pregnant woman cannot be excluded. 
Modulation of the fibrinolytic system by low-dose aspi- 
rin could be of particular importance after normal 
placental separation, when coagulation in the placental 
bed is balanced by a marked increase in fibrinolytic 
capacity.” 
In this study we compared variables of fibrinolysis 
and thromboxane and PGI, synthesis at the end of 
pregnancy before and immediately after parturition in 
women receiving low-dose aspirin for prevention of 
preeclampsia or fetal growth retardation and in women 
who had not taken aspirin. Because exact definition of 
the timing of sampling could be important in an inves- 
tigation on fibrinolytic variables, we conducted this 
study in plasma of women in whom labor was induced, 
which allowed standardization of sampling times. In 
addition, we investigated the effect of low-dose aspirin 
on fibrinolytic variables in cord blood. 
Material and methods 
Patients. Twenty-four healthy pregnant women were 
enrolled in the study. Of these, eight took a daily dose 
of 60 to 80 mg of aspirin (1 mgikg body weight) from 
12 weeks’ gestation until delivery because of a history of 
preeclampsia or fetal growth retardation; 16 women 
who did not use aspirin during pregnancy served as 
controls. All women opted for elective induction of 
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labor, an accepted procedure in the department.‘” Cer- 
vical ripeness was assessed with the Burnhill score.” 
When the cervix was considered favorable, the mem- 
branes were ruptured, and a fluid-filled open-tip cath- 
eter was introduced transcervically into the amniotic 
cavity for the recording of uterine activity. An electrode 
was attached to the fetal scalp for fetal heart rate 
monitoring. Uterine contractions were induced with 
intravenous infusion of an incremental dose of oxytocin 
starting with 2 mU/min until a uterine activity of 150 to 
200 Montevideo units was obtained.” In all cases in- 
duction of labor started at 8 AM. Low-dose aspirin users 
took the last tablet at 7 AM. The study protocol as 
approved by the University and Hospital Ethics Com- 
mittee was explained, and informed consent was ob- 
tained in all cases. 
Blood sampling. Maternal venous blood samples 
were taken 5 minutes before the start of the oxytocin 
infusion and within 5 minutes after delivery of the 
placenta. All samples were obtained from an antecubital 
vein without occlusion through a 19-gauge needle. 
A sample of 4.5 ml was collected in tubes containing 
0.5 ml of 0.11 mol/L sodium citrate, 15 mmol/L the- 
ophylline, 3.7 mmol/L adenosine, and 0.198 mmol/L 
dipyridamole, pH 5.5 (Becton Dickinson, Meylan, 
France) for determination of tPA antigen, plas- 
minogen activator inhibitor type-l (PAI-1) and type-2 
(PAI-2) antigen and plasminogen activator inhibitor 
activity. Another 4.5 ml sample was collected in Stabi- 
lyte tubes (Biopool, Umea, Sweden, containing 0.5 ml 
of 0.45 mol/L sodium citrate buffer, pH 4.3) for deter- 
mination of tPA activity. A 9 ml sample was taken in a 
plastic tube in 1 ml of disodium ethylenediaminetet- 
raacetate for determination of synthesis of malondial- 
dehyde by stimulated platelets. For determination of 
6-keto-prostaglandin F,, (PGF,,), a stable metabolite of 
PGI,, a 5 ml sample was collected in cooled plastic 
tubes containing 10 ~1 of heparin and 25 ~1 of indo- 
methacin (0.1% in potassium-phosphate buffer 0.1 
mol/L, pH 7.4). Finally, a 5 ml blood sample was 
collected in glass tubes and allowed to clot for determi- 
nation of serum levels of thromboxane B, (TXB,). 
Samples of mixed free-flowing cord blood were col- 
lected immediately after clamping of the cord with the 
placenta in situ for determination of the same set of 
variables. 
Analytic procedures. Samples for determination of 
variables of fibrinolysis were transported on melting ice, 
centrifuged for 30 minutes at 20009 at 4” C, and stored 
at -70” C until analysis. Samples for determination of 
plasma PGF,, were centrifuged for 10 minutes at 15OOg 
at 0” C and stored at - 20” C until analysis. The clotted 
blood samples for determination of serum TXB, were 
incubated for 60 minutes at 37” C to stimulate maxi- 
mum platelet TXB, release. After centrifugation for 10 
minutes at 25009 at 20” C serum samples were kept at 
- 20” C until analysis. 
tPA antigen was determined with a commercially 
available enzyme immunoassay (Imulyse, Biopool) that 
measures both free and complexed tPA in the range of 
1.5 to 30 ngiml. The maximal sensitivity of the test was 
1.5 rig/ml; intraassay variation was 8% and interassay 
variation 10%. 
tPA activity was determined by the conversion of 
plasminogen to plasmin in the presence of soluble 
fibrinogen fragments by means of a chromogenic sub- 
strate according to Verheijen et a1.l4 The detection limit 
of this assay was 50 mIU/ml; intraassay variation was 5% 
to 13%, and interassay variation was 15% to 20%. 
PAI- antigen was measured with a commercially 
available enzyme immunoassay that used anti-PAI- 1 
antibodies (TintElize PAI-1, Biopool). The test mea- 
sures both fi-ee PAI- and PAI- complexed to activa- 
tors. The detection limit was 2 rig/ml PAI-1; the intraas- 
say variation was 2% at 40 rig/ml and 7% at 15 rig/ml. 
PAl activity was measured by titration of diluted 
samples with tPA according to Verheijen et a1.15 Results 
are expressed as a percentage of a standard normal 
plasma pool obtained from 40 healthy volunteers. In- 
traassay variation was 2% to lo%, and interassay varia- 
tion was 10% to 15%. 
PAI- antigen was determined with a commercially 
available enzyme immunoassay that used anti-PAT-2 
antibodies (TintElize PAI-2, Biopool). The detection 
limit was 6 ngiml. 
The capacity of platelets to synthesize thromboxane 
AZ was determined within 30 minutes after venipunc- 
ture by measuring the amount of its stable by-product 
malondialdehyde produced on stirring platelet-rich 
plasma with thrombin (1 IU/ml final concentration), as 
described previously.‘@ The concentration of malondi- 
aldehyde was measured by means of the thiobarbituric 
acid reaction and expressed as nanomoles of malondi- 
aldehyde produced by 10’ platelets. 
Plasma concentrations of PGF,, and serum TXB, 
levels were determined by radioimmunoassay (E.I. Du 
Pont de Nemours-NEN Research Products, Boston). A 
Sep-Pak Cl8 cartridge (Waters, Milford, Mass.) was 
prewashed with 10 ml of absolute ethanol, 10 ml of 
distilled water, and 2 ml of air. Two milliliters of the 
sample was applied to the column, followed by 2 ml of 
distilled water and 2 ml of air. The prostaglandin 
metabolites were eluated with 2 ml of absolute ethanol, 
followed by 2 ml of air, and the eluate was brought to 
dryness at 40” C under a gentle stream of nitrogen. The 
residue was dissolved in radioimmunoassay buffer, and 
the assay was performed with iodine 125-labeled anti- 
gen according to the instruction manual.” 
Statistical analysis. Because the results could not be 
expected to follow a normal distribution, data are 
988 Bremer et al. March 1995 
Am J Obstet Gynecol 
Table I. General characteristics of women who participated in the study (median, range) 
Age W) 
Parity 
Duration of use of low-dose aspirin (wk) 
Gestational age (wk) 
Birth weight (gm) 
Estimated blood loss at delivery (ml) 
Aspirin (n = 8) 
32 (26-38) 
1 (l-4) 
25.5 (22-28) 
38.5 (37.4-40.2) 
3305 (2780-3715) 
200 (100-600) 
Control (n = 16) 
30 (20-41) 
1 (l-7) 
39.4 (36.5-42) 
3235 (2670-4160) 
200 (100-I 100) 
Table II. Median (interquartile range) concentrations of variables of fibrinolysis in maternal venous plasma 
Plasma Aspirin (n = 8) 
tPA antigen (ngiml) 10.8 (6.2-12.6) 
tPA antigen (ng/ml)b 17.6 (14.9-27.2) 
Significance? p = 0.01 
tPA activity (IUiml) 0.8 (0.6-1.1) 
tPA activity (lU/ml)b 2.8 (1.6-3.8) 
Significance? p = 0.01 
PAI- antigen (rig/ml 101.9 (52.6-127.5) 
PAI- antigen (rig/ml)” 44.9 (42.9-62.7) 
Significancet p = 0.01 
PAI- antigen (ngiml) 168 (146.5-209.8) 
PAI- antigen (ng/ml)b 160.5 (128.8-193.8) 
Significancet NS 
Plasminogen activator inhibitor activity (%)” 326 (86-428) 
Plasminogen activator inhibitor activity (%)b 108 (70-167) 
Significance+ p = 0.01 
Control (n = 16) 
6.5 (4.2-16.4) 
13.9 (10.5-29.3) 
p < 0.001 
1.0 (0.4-1.6) 
1.7 (1.0-2.7) 
p = 0.003 
101.5 (66.9-134) 
66.2 (38.2-80.2) 
p < 0.001 
189 (134.4-225.8) 
165.5 (130.8-192.8) 
p = 0.03 
556 (431-829) 
339 (100-528) 
p < 0.001 
Significance” 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
p = 0.02 
p = 0.02 
NS, Not significant. 
*Aspirin versus control. 
tValues obtained 5 minutes before oxytocin infusion (a) versus values 5 minutes after delivery of placenta (bi. 
expressed as medians with 25th and 75th percentiles or 
range. Differences between time-related continuous 
variables were assessed with the Wilcoxon signed-rank 
test. Comparisons between maternal and cord samples 
and between aspirin and control groups were made 
with the Wilcoxon rank-sum test. Relationships between 
maternal and cord variables were analyzed with Spear- 
man’s rank correlation test. All p values are two-tailed, 
and a level of <0.05 is considered to represent sig- 
nificance. 
Results 
General characteristics of the women who partici- 
pated in the study are summarized in Table I. None of 
the aspirin-treated women had a pregnancy-induced 
hypertensive disorder or fetal growth retardation. All 
deliveries were uncomplicated and resulted in live, 
healthy infants. 
Effects of labor and delivery on fibrinolytic markers 
are presented in Table II. Concentrations of tPA anti- 
gen, tPA activity, PAI- antigen, and PAI- antigen 
before labor and after delivery of the placenta were not 
different between aspirin users and controls. Plasmino- 
gen activator inhibitor activity was significantly reduced 
in the aspirin group compared with controls, before 
and after parturition (p = 0.02). 
Both tPA antigen and activity rose, whereas PAI- 
antigen and plasminogen activator inhibitor activity 
decreased significantly during labor and delivery. These 
changes were not affected by low-dose aspirin and were 
not related to the duration of labor. PAI- antigen 
showed a small but significant @ = 0.03) reduction 
during parturition in the control group that could not 
be demonstrated in low-dose aspirin users. No signifi- 
cant correlations were demonstrated between the levels 
of fibrinolytic variables in maternal and cord plasma. 
Comparison of fibrinolytic variables in cord blood in 
the aspirin and control groups showed no significant 
differences (Table III). 
Levels of PGF,, before labor in the aspirin group (me- 
dian 54.7 rig/L, range 52 to 82.8 rig/L) were about 14% 
lower than in controls (median 63.3 rig/L, range 50.6 to 
73 rig/L), but the difference was not significant. Fig. 1, A 
and B, shows the significant increase in PGF,, in mater- 
nal plasma during parturition; no significant differences 
could be demonstrated between the aspirin and control 
groups. Cord plasma levels of PGF,, were not different 
between groups and were about 14 times higher than 
maternal plasma concentrations (p < 0.001). 
Before labor maternal malondialdehyde formation in 
the aspirin group (median 0.52 nmol/lO’ platelets, 
range 0.48 to 1.00 nmol/lO’ platelets) and serum TXB, 
concentrations (median 20.8 pg/L, range 12.0 to 40.2 
pg/L) were significantly lower than those in controls 
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Fig. 1. A and B, Maternal venous and cord plasma levels of 6-keto-PGF,, in women receiving 
long-term low-dose aspirin (A) compared with controls not taking aspirin (B). 1, Before parturition; 
2, after parturition; 3, cord plasma. Asterisk, Compared with maternal plasma 2. 
Table III. Median (interquartile range) concentrations of variables of fibrinolysis and prostanoid 
metabolites in cord blood 
Aspitin (n = 8) Control (n = 16) Signtjkance 
tPA antigen (ngiml) 
tPA activity (IUlml) 
PAI- 1 antigen (rig/ml) 
Plasminogen activator inhibitor activity (%) 
PAI- antigen (ngiml) 
6-keto-PGF,, (rig/L) 
-I’J%! (w/L) 
Malondialdehyde (nmol/lOg platelets) 
4.5 (2.3-26) 
7.5 (2.9-8.9) 
14.9 (10.6-77) 
43 (25-100) 
3.7 (0.5-68.2) 
626 (326-1164) 
37.8 (27.7-80) 
2.2 (1.9-2.7) 
4.5 (3.2-7.5) 
3.0 (1.5-11) 
21.2 (17.8-50) 
49 (23-78) 
6.6 (3.2-27) 
862 (471-1182) 
217 (123-326) 
5.2 (4.7-5.8) 
NS 
NS 
NS 
NS 
NS 
p = Y.ioo2 
p = 0.0001 
NS, Not significant. 
(malondialdehyde median 5.4 nmol/lO’ platelets, range 
4.7 to 6.4 nmoVl0” platelets; TXB, median 281 pg/L, 
range 205 to 411 kg/L; p < 0.0001). No significant 
changes were observed in platelet malondialdehyde 
formation and in serum TXB, concentrations during 
parturition in aspirin users and in controls. 
In the control group no differences could be demon- 
strated between platelet malondialdehyde synthesis and 
serum TXB, concentrations in maternal and cord 
samples, but in low-dose aspirin users malondialdehyde 
synthesis and serum TXB, concentrations were sig- 
nificantly reduced in maternal compared with cord 
samples @ < 0.001). 
Comment 
Results of previous studies suggest that a daily dose 
of 60 to 80 mg of aspirin has no demonstrable effect on 
hemostasis in pregnant women, as indicated by the 
bleeding time, ‘*, I9 but no data could be found in the 
accessible literature on the effect on the fibrinolytic 
system. Throughout pregnancy marked alterations oc- 
cur in the fibrinolytic system, characterized by increases 
in plasma concentrations of tPA and its inhibitors PAI- 
and PAI- until the end of the thirty-eighth week of 
pregnancy, after which plasma concentrations of all 
these substances decrease, except those of tPA anti- 
gen.“’ In a recent report on the effects of parturition on 
fibrinolysis a significant increase in maternal plasma 
concentrations of tPA antigen during labor was demon- 
strated, with a marked further increase in fibrinolytic 
potential after placental separation.*’ In previous stud- 
ies a high dose of aspirin (650 mg) ingested 18 and 2 
hours before blood sampling was shown to inhibit the 
release of tPA antigen by vascular endothelium induced 
by venous occ1usion.5’ ’ A study of the effect of 20 mg of 
aspirin taken for 7 consecutive days showed no signifi- 
cant effect on fibrinolytic activity, measured by the 
euglobulin lysis area and the euglobulin lysis time.’ In 
our study no effect of the long-term use of low-dose 
aspirin on tPA activity was observed. The only fibrino- 
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lytic variable affected by the use of low-dose aspirin 
during pregnancy was plasminogen activator inhibitor 
activity, which was significantly reduced in the aspirin 
group before and after labor. This could lead to a 
relative dominance of tPA activity over plasminogen 
activator inhibitor and hence to an increased fibrino- 
lytic potential in low-dose aspirin users. The question 
whether this causes an increase in effective fibrinolysis 
in vivo remains to be answered. The observed signifi- 
cant changes in levels of all fibrinolytic markers during 
parturition, except PAI-2, may be caused by vascular 
damage in the uterine placental bed” and appear to 
remain unaffected by low-dose aspirin. In the nonpreg- 
nant state diurnal variations in blood fibrinolytic activity 
are caused by changes in the plasma levels of PAI-I, 
which are highest in the early morning and lowest in 
the late afternoon.‘3 However, plasminogen activator 
inhibitor production is not influenced by diurnal varia- 
tions in populations with high plasminogen activator 
inhibitor levels, as in pregnancy.24 Because of the stan- 
dardization of our study, all samples were obtained at 
approximately the same time of the day, which makes a 
contribution of circadian variation to the results un- 
likely. 
We could not demonstrate an inhibitory effect of the 
long-term intake of 60 to 80 mg of aspirin on maternal 
PGI, synthesis, which confirms earlier observations by 
ourselves” and by others.” The observed increased 
synthesis of PGI, during labor confirms earlier obser- 
vation?” and appears also to be unaffected by low-dose 
aspirin. 
It is known that in normal pregnancy platelet reac- 
tivity increases, not only in association with increasing 
activity of the cyclooxygenase pathway but also with an 
elevated sensitivity of the platelet membrane.“7 Previous 
studies have shown that approximately 90% to 95% 
inhibition of maternal platelet reactivity can be 
achieved with a daily dose of 60 mg of aspirin,“, ” as 
confirmed in the current study. Negatively charged 
phospholipids are known to stimulate plasminogen ac- 
tivator inhibitor activity,“’ and platelets, offering a net 
negative charge on activation, may provide a site for 
activation of plasminogen activator inhibitor.30 There- 
fore the reduced platelet reactivity induced by low-dose 
aspirin could be responsible for the reduced plasmino- 
gen activator inhibitor activity in the aspirin group. 
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Angiotensin-converting enzyme activity and contractile 
effects of angiotensin I and II in human 
uteroplacental arteries 
Danny Svane, MD, PhD,” Ole Kahr, MD,b Vibeke B. Hansen, MD,” 
Peter Holm-Nielsen, MD,’ and Axe1 Forman, MD, PhD” 
Aarhus, Denmark 
OBJECTIVE: Our purpose was to study local angiotensin-converting enzyme activity and the mechanical 
effects of angiotensin I and II in human uteroplacental arteries. 
STUDY DESIGN: Angiotensin-converting enzyme activity was measured by a simple radioimmunoassay 
with tritiated benzoyl-glycyl-glycyl-glycine as substrate in isolated human intramyometrial arteries from 
nonpregnant (n = 8) and term pregnant women (n = 8) and placental (n = 8) stem villous arteries. 
Moreover, in these vessels the mechanical effects of angiotensin I and II were investigated in organ bath 
experiments. Endothelium-intact and endothelium-denuded arteries were used, and the integrity of the 
endothelium was examined by histologic studies. 
RESULTS: The activity of angiotensin-converting enzyme ranked the intramyometrial arteries from 
pregnant women > > intramyometrial arteries from nonpregnant women zfetal stem villous arteries. 
Angiotensin-converting enzyme activity was unaffected by removal of the endothelium. Angiotensin II 1O-5 
mol/L produced contractile responses in the intramyometrial arteries without significant differences 
between arteries from nonpregnant and pregnant women. In fetal stem villous arteries the effects of 
angiotensin II 1 Od5 mol/L were less pronounced. As for angiotensin II, the contractile responses to 
angiotensin I 1 Om5 mol/L showed marked development of tachyphylaxis. In the endothelium-denuded 
preparations the contractile responses to angiotensin I 10e5 mol/L were significantly enhanced in 
intramyometrial arteries from nonpregnant women but remained unchanged in intramyometrial arteries 
from pregnant women and in fetal stem villous arteries. In all preparations pretreatment with captopril or 
perindopril (1 Om5 mol/L) markedly reduced angiotensin-converting enzyme activity, whereas no effects 
were observed on the contractile responses to angiotensin I. Saralasin 1 Om5 mol/L completely abolished 
the contractile responses to angiotensin I and II. 
CONCLUSION: Local angiotensin-converting enzyme activity in human intramyometrial arteries seems to 
be markedly increased during pregnancy and shows marked differences between maternal and fetal 
uteroplacental arteries. High concentrations of angiotensin I may imply direct effects on the angiotensin II 
receptor independent of the local angiotensin-converting enzyme activity. (AM J OBSTET GYNECOL 
1995;172:991-7.) 
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